Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen.

Medicine (Baltimore) · 2021 · PMC8389919 · PMID 34449491

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, the cases who switched from a non-INSTI containing regimen to TAF + DTG did experience the largest amount of weight gain as compared to those switched from non-INSTI to TAF + elvitegravir or TAF + BIC, although the difference did not reach statistical significance given the small sample sizes.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.